Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 8/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 12/20 | 0.52 |
| ▸ | TSHR | P16473 | 6/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CHKA | P35790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11947816 | 0.93 | CYP3A4 (0.61) | CYP2C19CYP2C9MAPK1MEN1KMT2A | |
| SCHEMBL11947818 | 0.93 | CYP2C9 (0.52) | CYP2C19CYP2C9MAPK1MEN1KMT2A | |
| SCHEMBL13131097 | 0.90 | CYP2C9 (0.54) | CYP2C19CYP2C9MAPK1MEN1KMT2A | |
| SCHEMBL11947861 | 0.89 | CYP3A4 (0.59) | CYP2C19CYP2C9MAPK1MEN1KMT2A | |
| SCHEMBL13131024 | 0.88 | CYP2C9 (0.54) | CYP2C19CYP2C9MAPK1MEN1KMT2A | |
| SCHEMBL11947832 | 0.87 | CYP2C9 (0.59) | CYP2C19CYP2C9MAPK1MEN1KMT2A | |
| SCHEMBL11947860 | 0.86 | CYP2C9 (0.64) | CYP2C19CYP2C9MAPK1MEN1KMT2A | |
| SCHEMBL11947838 | 0.85 | CYP3A4 (0.54) | CYP2C19CYP2C9MAPK1MEN1KMT2A | |
| SCHEMBL11947824 | 0.84 | CYP2C9 (0.53) | CYP2C19CYP2C9MAPK1MEN1KMT2A | |
| SCHEMBL11947859 | 0.83 | CYP2D6 (0.59) | CYP2C19CYP2C9MAPK1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| US-8455475-B2 | Substituted spiro-amide compounds | GRUENENTHAL GMBH (DE) | 2013-06-04 | — | — | US | disclosed |
| US-8232288-B2 | Substituted benzimidazoles, benzothiazoles and benzoxazoles | GRUENENTHAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-20110009382-A1 | Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles | GRUENENTHAL GMBH (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | BDKRB1, BDKRB2, REN | CYP2C19 2325/4885CYP2C9 2259/4885MAPK1 1001/4885 |
| US-20110009382-A1 | Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles | BDKRB1, BDKRB2, BRD1 | CYP2C19 247/4885CYP2C9 362/4885MAPK1 570/4885 |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | BDKRB1, BDKRB2, REN | CYP2C19 2325/4885CYP2C9 2259/4885MAPK1 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.